SITC Guidelines Bundle

Immunotherapy for Bladder Cancer

SITC GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/953721

Contents of this Issue

Navigation

Page 7 of 7

Disclaimer This Guideline a empts to define principles of prac ce that should produce high-quality pa ent care. It is applicable to specialists, primary care providers and ancillary healthcare providers. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ul mate judgment concerning the propriety of any course of conduct must be made by the clinician a er considera on of each individual pa ent situa on. Neither IGC, SITC, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2017 All rights reserved SITCBLAD1793c Defini on of Evidence Grades Level Defini on A Strong suppor ng evidence-based data from prospec ve, randomized, controlled trials, meta-analyses, long-term follow-up of prospec ve, uncontrolled trials B Moderate suppor ng data from uncontrolled, prospec ve clinical trials C Weak suppor ng data from retrospec ve reviews and case reports Percentages Propor on of Task Force members favoring recommenda on Abbrevia ons AUA, American Urologic Associa on; BCG, Bacillus Calme e-Guérin; CIS, carcinoma in situ; DDMVAC, dose-dense methotrexate, vinblas ne, doxorubicin, and cispla n; dMMR, mismatch repair-deficient; EAU, European Associa on of Urology; FDA, U.S. Food and Drug Administra on; IBCG, Interna onal Bladder Cancer Group; ICUD, Interna onal Consulta on on Urological Diseases; MSI-H, Microsatellite instability-high; NAM, Na onal Academy of Medicine; NCCN, Na onal Comprehensive Cancer Network; NMIBC, non-muscle invasive bladder cancer; SITC, Society for Immunotherapy of Cancer; TUR, transurethral resec on Source Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA 3rd, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer. 2017 Aug 15;5(1):68. Lamm DL, Blumenstein BA, Crissman JD, Mon e JE, Go esman JE, Lowe BA, et al. Maintenance bacillus Calme e-Guérin immunotherapy for recurrent Ta,T1 and carcinoma in situ TCC of the bladder: A randomized SWOG study. J Urol. 2000;163:1124–9. PMID: 10737480

Articles in this issue

Links on this page

Archives of this issue

view archives of SITC Guidelines Bundle - Immunotherapy for Bladder Cancer